We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.66%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$89.3B
AUM Growth
+$8.23B
(+10%)
Cap. Flow
+$1.9B
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
24.87%
Holding
4,460
New
1,490
Increased
1,679
Reduced
1,235
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$60.1M |
| 2 |
TSMC
TSM
|
+$59.1M |
| 3 |
Tesla
TSLA
|
+$56M |
| 4 |
Apple
AAPL
|
+$55.2M |
| 5 |
Amazon
AMZN
|
+$47.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI ACWI ex US ETF
ACWX
|
+$102M |
| 2 |
Everest Group
EG
|
+$27.4M |
| 3 |
Chevron
CVX
|
+$25M |
| 4 |
Wells Fargo
WFC
|
+$24.9M |
| 5 |
Crane NXT
CXT
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.27% |
| 2 | Healthcare | 12.98% |
| 3 | Financials | 12.17% |
| 4 | Consumer Discretionary | 11.18% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3751
Friedman Industries
FRD
$272M
| $3.33K | ﹤0.01% |
+264
| New | +$2.8K |
|
|
YELL
3752
DELISTED
Yellow Corporation Common Stock
YELL
| $3.32K | ﹤0.01% |
+4,813
| New | +$7.52K |
|
|
FXLV
3753
DELISTED
F45 Training Holdings Inc.
FXLV
| $3.26K | ﹤0.01% |
6,522
-40,328
| -86% | -$34.3K |
|
|
CELL
3754
DELISTED
PhenomeX Inc. Common Stock
CELL
| $3.26K | ﹤0.01% |
6,647
-81,699
| -92% | -$66.8K |
|
3755
Alaunos Therapeutics
TCRT
$4.86M
| $3.25K | ﹤0.01% |
+42
| New | +$3.4K |
|
|
VRNA
3756
DELISTED
Verona Pharma
VRNA
| $3.23K | ﹤0.01% |
+153
| New | +$3.26K |
|
|
JFU
3757
9F Inc
JFU
$29.1M
| $3.21K | ﹤0.01% |
+954
| New | +$3.5K |
|
|
VIEW
3758
DELISTED
View, Inc. Class A Common Stock
VIEW
| $3.21K | ﹤0.01% |
443
-2,641
| -86% | -$39.7K |
|
|
LFLY
3759
DELISTED
Leafly Holdings, Inc. Common Stock
LFLY
| $3.18K | ﹤0.01% |
549
-567
| -51% | -$3.85K |
|
|
ADAG
3760
Adagene
ADAG
$274M
| $3.15K | ﹤0.01% |
+2,215
| New | +$3.04K |
|
|
LNAI
3761
Lunai Bioworks
LNAI
$11M
| $3.13K | ﹤0.01% |
69
-312
| -82% | -$23.9K |
|
3762
Ultralife
ULBI
$88.6M
| $3.13K | ﹤0.01% |
+646
| New | +$2.81K |
|
3763
Wheels Up
UP
$197M
| $3.12K | ﹤0.01% |
133
-1,068
| -89% | -$75.5K |
|
|
NEXN
3764
Nexxen International
NEXN
$610M
| $3.1K | ﹤0.01% |
+430
| New | +$2.64K |
|
|
DOMA
3765
DELISTED
Doma Holdings, Inc.
DOMA
| $3.09K | ﹤0.01% |
625
-7,614
| -92% | -$61.1K |
|
|
LUXE
3766
LuxExperience B.V.
LUXE
$1.1B
| $3K | ﹤0.01% |
+750
| New | +$3.57K |
|
3767
FreightCar America
RAIL
$253M
| $2.98K | ﹤0.01% |
+1,001
| New | +$2.89K |
|
|
AFMD
3768
DELISTED
Affimed
AFMD
| $2.95K | ﹤0.01% |
494
-17,797
| -97% | -$143K |
|
|
VIOT
3769
Viomi Technology
VIOT
$50.1M
| $2.94K | ﹤0.01% |
+3,340
| New | +$3K |
|
3770
CEL-SCI Corp
CVM
$28.1M
| $2.94K | ﹤0.01% |
+41
| New | +$2.98K |
|
|
AUTL
3771
Autolus Therapeutics
AUTL
$532M
| $2.92K | ﹤0.01% |
+1,228
| New | +$2.91K |
|
|
GNFT
3772
DELISTED
Genfit
GNFT
| $2.84K | ﹤0.01% |
+803
| New | +$3.31K |
|
3773
Assembly Biosciences
ASMB
$524M
| $2.76K | ﹤0.01% |
+200
| New | +$2.46K |
|
3774
Immunocore
IMCR
$1.75B
| $2.76K | ﹤0.01% |
+46
| New | +$2.63K |
|
|
EVAX
3775
Evaxion A/S
EVAX
$25M
| $2.74K | ﹤0.01% |
+42
| New | +$2.93K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, RhumbLine Advisers held 4,460 positions worth $89.3B, up 10% from $81B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
RhumbLine Advisers's Q2 2023 filing shows 1,490 new, 1,679 increased, 1,235 reduced and 38 closed positions. Its largest new stake was TSMC: 635,517 shares worth $64.1M. The largest sale was iShares MSCI ACWI ex US ETF, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q2 2023 buy was TSMC: 635,517 shares worth $64.1M.
- RhumbLine Advisers added most to Microsoft in Q2 2023, an estimated $60.1M increase.
- RhumbLine Advisers's biggest Q2 2023 reduction was iShares MSCI ACWI ex US ETF, cutting an estimated $102M.
- RhumbLine Advisers fully exited Everest Group in Q2 2023, selling an estimated $27.4M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $89.3B portfolio in Q2 2023.
- RhumbLine Advisers opened 1,490 new positions and closed 38 in Q2 2023.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $89.3B.
Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.